CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates Good response to tolvaptan shortens hospitalization in patients with congestive heart failure Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure Can We Use the Intrinsic Left Ventricular Delay (QLV) to Optimize the Pacing Configuration for Cardiac Resynchronization Therapy With a Quadripolar Left Ventricular Lead? HFpEF: From Mechanisms to Therapies Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist Systems Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators - The RAID Trial Heart failure with preserved ejection fraction: from mechanisms to therapies

Clinical TrialFebruary 6, 2018, Volume 137, Issue 6

JOURNAL:Circulation Article Link

Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study

M .Kosiborod, CVD-REAL Investigators and Study Group. Keywords: SGLT2 inhibitor; death; diabetes mellitus; heart failure; observational studies

FULL TEXT PDF